NCT02494804View on ClinicalTrials.gov

Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2030

Conditions
Cytokine-Induced Killer CellsMilignant Gliomas
Interventions
DRUG

Temozolomide

Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days

BIOLOGICAL

CIK

The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER

NCT02494804 - Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas | Biotech Hunter | Biotech Hunter